Illustration for: Forus Triples Valuation To $3B In Series C

Forus Triples Valuation To $3B In Series C

Forus raised a $150 million Series C led by Bain Capital Ventures at a $3 billion valuation, tripling its worth months after its Series B, as its AI agents automate prescription prior authorization for providers nationwide.

By the Numbers

$150M
Series C
$3B
New valuation
$300M+
Total raised
2023, NYC
Founded
85% of US ZIPs
Coverage
ForusBain Capital Ventures
TC
By the Funding Desk
Edited by Trace Cohen · Early-stage VC & angel · Founder, New York Venture Partners
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Forus is free to providers and patients, which puts the revenue with payers and pharma -- the same parties whose prior-authorization friction the software exists to remove, a structural tension no valuation step-up resolves.

2

A $3 billion mark is roughly 2.5 times what McKesson paid for CoverMyMeds in 2017, a company founded in 2008 in the same prior-auth category -- private AI multiples are now priced well past the strategic exit comp for this workflow.

3

Tripling months after the Series B with Thrive, General Catalyst, Accel and Redpoint all re-upping means the step-up rests on Bain Capital Ventures alone as new price-setter, on a model untested through a full reimbursement cycle.

4

Reaching providers in 85% of U.S. residential ZIP codes across all 50 states is the defensible asset: CoverMyMeds, Cohere Health and Rhyme all attack the same workflow, and distribution, not the agent, is the hard part to copy.

TC

The VC Read · Trace's Take

Trace Cohen

Forus tripling to a $3B valuation in months, on top of a free-to-provider model, is the part worth diligencing -- the revenue sits entirely with payers and pharma, the same parties whose prior-auth friction Forus is paid to reduce. CoverMyMeds sold to McKesson for roughly $1.2B in 2017; Forus is already 2.5x that on a model untested through a full reimbursement cycle.

AI Landscape →

Analysis

Forus, an AI health company formerly known as Tandem, raised a $150 million Series C led by Bain Capital Ventures at a $3 billion valuation, according to Bloomberg. Existing investors Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures and SV Angel all joined, pushing total funding past $300 million.

Founded in New York in 2023 by Sahir Jaggi, Forus deploys AI agents inside the prescribing workflow: when a doctor writes a prescription, the software checks medication history, verifies payer coverage, files prior-authorization paperwork, handles appeals after insurance denials, and routes the order to a pharmacy without staff intervention. The company says its network now reaches providers in 85% of U.S. residential ZIP codes across all 50 states, offered free to providers and patients.

“The company says its network now reaches providers in 85% of U.S.”

Forus competes against:

  • CoverMyMeds -- founded 2008, acquired by McKesson in 2017 for roughly $1.2 billion.
  • Cohere Health -- founded 2019, focused on health-plan-side automation.
  • Rhyme -- an Ohio-based prior-authorization specialist founded in 2016.
ShareXLinkedInEmail

More on

Forus →Bain Capital Ventures →

Prior Pulse Coverage

ForusForus Triples to a $3B Value in Four Months

Key Sources

2 sources
SourceBloomberg
AnalysisValue Add Pulse

Reported by Bloomberg · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

FUNDING

The Fed Just Hiked Rates. AI Capital Didn't Blink.

FUNDING

Arcee AI Hits $1B+ Valuation Building Open-Weight Models

FUNDING

Impulse Space Adds $308M, Valuation Jumps To $5.6B

Deep Dives

Hadrian Raises $1.37B Series D at $7.87B ValuationWrtn Technologies Valuation 2026: South Korea's AI App Hi...Upwind Security Valuation: $3.8B After $300M Round